ライフサイエンスコーパス: prostatitis

1 The d3tx male mice also developed autoimmune prostatitis.

2 the pathologically defined focus of chronic prostatitis.

3 imaging abnormality in the region of chronic prostatitis.

4 hat PAP-specific CTLs can induce destructive prostatitis.

5 pathogenic E. coli virulence factor in acute prostatitis.

6 tes to E. coli virulence in a model of acute prostatitis.

7 er than Abs, mediates destructive autoimmune prostatitis.

8 e most likely secondary to radiation-induced prostatitis.

9 uced rapid and severe destructive autoimmune prostatitis.

10 oes not generate CTL or result in autoimmune prostatitis.

11 tant microorganisms in patients with chronic prostatitis.

12 for the prophylaxis or treatment of MDR-GNB prostatitis.

13 sy and possibly for the treatment of MDR-GNB prostatitis.

14 er and grade were positively correlated with prostatitis.

15 and compared with mice without induction of prostatitis.

16 l culture and in a murine model of bacterial prostatitis.

17 ical disease including urinary retention and prostatitis.

18 at immunity to SVS2 was sufficient to induce prostatitis.

19 s and central tolerance, develop spontaneous prostatitis.

20 published epidemiologic research on chronic prostatitis.

21 may provide clues to the etiology of chronic prostatitis.

22 pinal cord injury victims, and patients with prostatitis.

23 res the links between sexual dysfunction and prostatitis.

24 eliable tests to diagnose chronic abacterial prostatitis?

25 .7 mm (5.7 +/- 2.4 ng/ml) or moderate/severe prostatitis (6 +/- 1.9 ng/ml).

26 ic mice with this regimen resulted in marked prostatitis accompanied by destruction of epithelium, in

27 fidence interval: 1.43, 2.15) or young-onset prostatitis (adjusted OR = 1.55, 95% confidence interval

28 mong women and is frequently misdiagnosed as prostatitis and benign prostatic hyperplasia among men.

29 elucidate the effects of GHRH antagonists in prostatitis and BPH.

30 Individuals having both moderate/severe prostatitis and CAL > or = 2.7 mm (10.8 +/- 7 ng/ml) had

31 eviously healthy 38-year-old male with acute prostatitis and concurrent Pseudomonas aeruginosa urosep

32 and, in particular, their associations with prostatitis and epididymitis.

33 ive technique that shows differences between prostatitis and PCa in both the peripheral zone and cent

34 e PSA levels between and among the groups of prostatitis and periodontitis.

35 Evidence linking prostatitis and prostate cancer development is contradic

36 plants, is widely used as a phytotherapy in prostatitis and prostate cancer.

37 ntributed to the development of nonbacterial prostatitis and prostate cancer.

38 ary tract infection and a rat model of acute prostatitis and that a striking feature of the histopath

39 ontinuous ductal system, eliciting bacterial prostatitis and/or epididymo-orchitis.

40 s (68%) in prostatodynia (chronic idiopathic prostatitis); and (iii) culture of difficult-to-grow cor

41 ents with benign prostate hyperplasia (BPH), prostatitis, and adenocarcinoma; and paraffin-embedded s

42 associated with strains from pyelonephritis, prostatitis, and bacteremia of urinary tract origin.

43 sexually transmitted infections, young-onset prostatitis, and frequency of ejaculation, were investig

44 benign prostatic hyperplasia (BPH) nodules, prostatitis, and healthy tissue were delineated on T2-we

45 gh-grade cancer specimens compared with BPH, prostatitis, and low-grade cancer.

46 ndard diagnostic test for chronic abacterial prostatitis, and the methodologic quality of available s

47 Men with recent prostate manipulation, prostatitis, and those on hormone therapy were excluded.

48 goal of this study is to develop autoimmune prostatitis as a therapy for prostate cancer.

49 at correlated with a diffuse area of chronic prostatitis at pathologic examination.

50 ancer and corresponded to a focus of chronic prostatitis at pathologic examination.

51 Half of all men experience symptoms of prostatitis at some time in their lives, but the etiolog

52 nts data suggesting that possible causes for prostatitis (bacterial or otherwise) may be explained un

53 ents were significantly higher than those in prostatitis, benign prostate hyperplasia, and normal pro

54 ct abnormalities of bacteriuria or bacterial prostatitis by traditional clinical tests, or of urethri

55 of (a) cancer versus NPZ, (b) cancer versus prostatitis, (c) prostatitis versus NPZ, and (d) high- o

56 er pathology) and few treatments for chronic prostatitis can be recommended on the basis of scientifi

57 category III), which accounts for 90%-95% of prostatitis cases, is of unknown etiology and is marked

58 Acute bacterial prostatitis (category I) and chronic bacterial prostatit

59 ostatitis (category I) and chronic bacterial prostatitis (category II) are characterized by uropathog

60 Asymptomatic inflammatory prostatitis (category IV) is an incidental finding of un

61 Treatment options for prostatitis caused by multidrug-resistant gram-negative

62 We show that acute prostatitis causes tissue damage and creates a tissue mi

63 Prostatitis [chronic prostatitis/chronic pelvic pain syn

64 In contrast, chronic prostatitis/chronic pelvic pain syndrome (category III),

65 Mental health disorders(MHD) in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) have

66 Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) in me

67 Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a

68 Prostatitis [chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)] is a

69 ts in the diagnosis and treatment of chronic prostatitis/chronic pelvic pain syndrome (CPPS).

70 of muscle) to better categorize male chronic prostatitis/chronic pelvic pain syndrome and interstitia

71 diagnosis, categorization, and treatment of prostatitis/chronic pelvic pain syndrome based on the Na

72 The etiology of chronic prostatitis/chronic pelvic pain syndrome in men is unkno

73 Treatment of chronic prostatitis/chronic pelvic pain syndrome is often empiri

74 Urologic pain conditions such as chronic prostatitis/chronic pelvic pain syndrome, interstitial c

75 p of prostate-associated bacteria to chronic prostatitis/chronic pelvic pain syndrome.

76 ential therapeutic target to control chronic prostatitis/chronic pelvic pain syndrome.

77 a valid model for the human disease chronic prostatitis/chronic pelvic pain syndrome.

78 mal DNA in the prostates of men with chronic prostatitis compared with controls are compatible with t

79 tions have been detected in men with chronic prostatitis compared with normal individuals, suggesting

80 Symptoms in men with chronic prostatitis/CPPS appear to cluster into a group with pri

81 The diagnosis of chronic prostatitis/CPPS must include conditions traditionally o

82 in conditions can be associated with chronic prostatitis/CPPS, including irritable bowel syndrome, fi

83 Chronic prostatitis (CPr) and benign prostatic hyperplasia (BPH)

84 Experimental autoimmune prostatitis (EAP) is considered a valid model for the hu

85 In autoimmune prostatitis (EAP) of the day-3 thymectomized (d3tx) mice

86 istories of sexually transmitted infections, prostatitis, ejaculation frequency, surgery for an enlar

87 Tissue samples of BPH and prostatitis exhibited higher mRNA and protein levels of

88 tic nephropathy, urinary bladder infections, prostatitis, gastric paresis, and impaired spermatogenes

89 ies show that microorganisms associated with prostatitis generally occur as complex microbial communi

90 Immunological studies of prostatitis have developed from findings of antibody coa

91 ity of CAL > or = 2.7 mm and moderate/severe prostatitis have higher PSA levels than those with eithe

92 a major target Ag of experimental autoimmune prostatitis in a rat model and may serve as a target Ag

93 Autoimmune prostatitis in Balb/C mice was induced by a homogenate o

94 generates a CTL response and tissue-specific prostatitis in the absence of detectable PAP-specific Ab

95 e developed significant nonbacterial chronic prostatitis in the prostate gland with notable infiltrat

96 IH classification types II, IIIa/IIIb and IV prostatitis) in the period of review (2001-2002).

97 Associations of prostatitis include benign prostatic hyperplasia, sexual

98 mal prostate, benign prostate hyperplasia or prostatitis indicating that Runx2 S319 phosphorylation i

99 mTmG model in concert with a murine model of prostatitis induced by infection from the uropathogenic

100 Chronic prostatitis is a common disease of unclear etiology and

101 ide direct evidence that spontaneous chronic prostatitis is an autoimmune disease and is regulated by

102 Prostatitis is an extremely common syndrome that afflict

103 idemiologic studies, it appears that chronic prostatitis is common.

104 The optimal management of chronic abacterial prostatitis is not known.

105 d alpha-blockers to treat chronic abacterial prostatitis is not supported by the existing evidence.

106 Formerly a purely clinical diagnosis, prostatitis is now classified within a complex series of

107 Epidemiological studies have confirmed that "prostatitis" is common, with a prevalence of 10-15%.

108 sometimes called prostatodynia or abacterial prostatitis, is a commonly diagnosed and poorly treated

109 specimens that contained regions of chronic prostatitis larger than 6 mm in the peripheral zone.

110 Acute prostatitis led to more proliferative epithelium and enh

111 Prostatitis-like symptoms such as perineal, penile, and

112 Median ADCs of normal prostate tissue, prostatitis, low-grade PCa (Gleason grade components 2 o

113 gest that the etiology of chronic idiopathic prostatitis may be of bacterial origin.

114 ic imaging, pathologically confirmed chronic prostatitis may demonstrate metabolic abnormality that l

115 that antibiotic therapy in chronic bacterial prostatitis may not be due to altered antibiotic pharmac

116 munities distinct from those associated with prostatitis may occur at low levels in normal prostatic

117 e prostate, and previous bouts of CD8-driven prostatitis may promote invasion in the Pten(+/-) model

118 However, 4 months after initiation of prostatitis, mice with induced inflammation had lower gr

119 pathologically identified regions of chronic prostatitis, MR spectroscopic imaging data in nine of 12

120 olates showed that pyelonephritis (n=23) and prostatitis (n=17) isolates exhibited more virulence fac

121 treatment of patients diagnosed with chronic prostatitis (NIH classification types II, IIIa/IIIb and

122 tal rectal examination, dysplastic glands or prostatitis on biopsy, ultrasound gland volume, urinary

123 ntigenic targets for experimental autoimmune prostatitis on the assumption that such proteins might a

124 ostate benign conditions (BCs) patients with prostatitis or prostate benign hyperplasia (BPH).

125 distinguish tumors from benign tissue (BPH, prostatitis, or healthy tissue) and high-grade tumors fr

126 s were seen for 65% of patients with chronic prostatitis overall.

127 NA sequence study after we found that 77% of prostatitis patients were PCR positive for prokaryotic r

128 ification of bacteria in prostate fluid from prostatitis patients.

129 ween periodontitis and PSA levels in chronic prostatitis patients.

130 y our observation that patients with chronic prostatitis possessed specific autoantibodies against th

131 ibacterium acnes, causative agent of chronic prostatitis possibly culminating in prostate cancer, is

132 ods were used to select 135 men with chronic prostatitis refractory to multiple previous courses of a

133 with inflammation, the contribution of CA to prostatitis-related symptoms of unknown etiology or to p

134 The therapeutics of chronic prostatitis remain as enigmatic as the disease.

135 rea of histopathologically confirmed chronic prostatitis, seven of 12 patients had focal low SI that

136 Here, we show that CP9-induced prostatitis significantly accelerates the initiation of

137 Chronic idiopathic prostatitis, sometimes called prostatodynia or abacteria

138 ing autoimmune dacryoadenitis and autoimmune prostatitis suppression.

139 with a National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) score of at least 1

140 ual function, continence, sleep quality, and prostatitis symptoms.

141 This review describes the current status of prostatitis syndromes and explores the future prospects

142 The etiology of chronic prostatitis syndromes in men is controversial, particula

143 mplex series of syndromes (NIH category I-IV prostatitis) that vary widely in clinical presentation a

144 he most common grade 3-4 adverse events were prostatitis (three [2%] in the vascular-targeted photody

145 rsus NPZ, (b) cancer versus prostatitis, (c) prostatitis versus NPZ, and (d) high- or intermediate-gr

146 0 tumor VOIs (26 high-grade), 36 BPH VOIs, 6 prostatitis VOIs, and 37 healthy-tissue VOIs.

147 eadache was 4% (2-9); chronic pelvic pain or prostatitis was 11% (8-17); and fibromyalgia was 4% (3-7

148 he most common MR imaging finding in chronic prostatitis was focal low SI that was not specific for c

149 flammation on Nxk3.1 accumulation, bacterial prostatitis was induced by intraurethral inoculation of

150 Moreover, prostatitis was induced in WT mice through immunization

151 Prostatitis was induced, and prostate bioluminescence wa

152 mice developed spontaneous inflammation, and prostatitis was similar among groups of mice at 8 and 12

153 link, the POET3 mouse, an inducible model of prostatitis, was crossed with a Pten-loss model of prost

154 During the 8-wk induction of chronic prostatitis, we detected a progressive increase in prost

155 ugh the median ADCs of biopsy specimens with prostatitis were significantly higher compared with low-

156 s been a recent surge of interest in chronic prostatitis, which hopefully will translate into advance